ClinicalTrials.gg
CompletedNCT00935012Updated Jan 5, 2021Results posted

Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy

A Phase 3 interventional study of tafamidis in ATTR-CM and TTR-CM, sponsored by Pfizer. Completed at 7 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-05.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 230 studies in Cardiomyopathies with a site in United States — 56 open to participants now, 68 under way, 6 of them phase 3. Cardiomyopathies · United States.

Enrollment
78th of 132
31 · median 42
Started
2009
with 5 others
Phase 3
18 of 230
5 open now
Registered
56th of 230
by date
Lead sponsor
5 of 230
Pfizer

Among the 230 studies in Cardiomyopathies with a site in United States, this one is the 78th largest by enrollment of the 132 interventional ones that give a count, is one of 6 that started in 2009, is one of 18 in phase 3, and was the 56th registered.

Cardiomyopathies

553 studies on the registry are indexed under Cardiomyopathies; 151 are open to participants now.

Browse Cardiomyopathies studies →

Open to participants now

56 of the 230 studies in Cardiomyopathies with a site in United States are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 115 Cardiomyopathies studies recruiting now, 70 (61%) set no upper age limit and 17 (15%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Cardiomyopathies with a site in United States, or all of them as a file.
02

Study summary

Open-label Safety and Efficacy Evaluation of Fx-1006a in Patients with V122i Or Wild-type Transthyretin (ttr) Amyloid Cardiomyopathy.

Patients who successfully complete Fx1B-201 will report to the clinical unit on Day 0 to sign the informed consent form and determine eligibility for Protocol Fx1B-303. In addition, on Day 0, patients will have their entrance criteria reviewed, and medical histories and demographic characteristics obtained.

The physical examination (including weight and vital signs) and the relevant end of study clinical laboratory tests (alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, gamma glutamyl transferase, creatinine, total bilirubin, international normalized ratio, troponin I, troponin T, and amino-terminal B-type natriuretic peptide) from Protocol Fx1B-201 will be used for Protocol Fx1B-303. If more than 30 days has elapsed between the final study visit of Protocol Fx1B-201 and Day 0 of Protocol Fx1B-303, an abbreviated physical examination (including weight and vital signs) and clinical laboratory assessments must be performed on Day 0.

Eligible patients will begin once-daily dosing with 20 mg Fx-1006A at home on Day 1 (i.e., first dose) and will return to the clinical unit for study visits every 6 months.

Adverse events (AEs) and concomitant medication use will be collected at each 6-month visit to the clinical unit. Blood draws for clinical safety laboratory tests and abbreviated physical examinations (including weight and vital signs) will also be performed at each 6-month clinic visit. ECGs will be performed every 12 months on an annual basis. A telephone call will be made at 3-month intervals between clinic visits to assess safety and use of concomitant medications.

For the evaluation of efficacy, the Patient Global Assessment, NYHA classification, KCCQ, 6-minute walk test, and efficacy-related clinical laboratory tests (serum levels of troponin T, troponin I, and NT-pro-BNP) will be determined every 6 months. In addition, echocardiograms will be performed every 12 months on an annual basis.

An end of study visit including all safety and efficacy assessments will occur upon patient completion of the study, premature withdrawal (for any reason), or in the event of program discontinuation by the Sponsor.

03

Conditions studied

  • ATTR-CM
  • TTR-CM

Keywords

  • TTR, ATTR, cardiomyopathy, amyloidosis, tafamidis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient successfully completed Protocol Fx1B-201.
  • If female; patient is post menopausal. If male, female partner is . If female is of child bearing potential, willing to use acceptable method of up to 3 months after last dose (included female partners of male participants).
  • Patient is willing to comply with protocol.

Exclusion criteria

Exclusion Criteria:

  • Patient did not successfully complete Fx1B-201.
  • Chronic use of NSAIDS.
  • Patient has a medication condition that increases risk of study participation.
  • Patient has received heart or liver transplant.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Open-Label

    Drug: tafamidis

Interventions

  • Once daily 20 mg oral tafamidis (soft gelatin capsule)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Categories of Patient Global Assessment (PGA) for Follow-up Visit: Month 12

    Participants overall quality of life was measured by PGA. At follow-up visit, participants were asked, "How do you feel today as compared to when we talked with you at your last clinic visit for this study?" and participants responded to any of the following: markedly improved, moderately improved, mildly improved, unchanged, mildly worsened, moderately worsened or markedly worsened.

    Time frame: Month 12

  2. Percentage of Participants With Categories of Patient Global Assessment (PGA) for Follow-up Visit: Month 60

    Participants overall quality of life was measured by PGA. At follow-up visit, participants were asked, "How do you feel today as compared to when we talked with you at your last clinic visit for this study?" and participants responded to any of the following: markedly improved, moderately improved, mildly improved, unchanged, mildly worsened, moderately worsened or markedly worsened.

    Time frame: Month 60

  3. Number of Participants Classified on the Basis of New York Heart Association (NYHA) Classification at Baseline

    NYHA classified participants in 4 classes. Class I included participants with cardiac disease without limitations of physical activity. Ordinary physical activity did not cause undue fatigue, palpitation, dyspnea, or anginal pain. Class II included participants with cardiac disease with slight limitation of physical activity. They were comfortable at rest. Ordinary physical activity resulted in fatigue, palpitation, dyspnea, or anginal pain. Class III included participants with cardiac disease with marked limitation of physical activity. They were comfortable at rest. Less than ordinary physical activity caused fatigue, palpitation, dyspnea, or anginal pain. Class IV included participants with cardiac disease with the inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome might be present even at rest. If any physical activity was undertaken, discomfort was increased.

    Time frame: Baseline

  4. Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Month 12

    NYHA classified participants in 4 classes: Class I: cardiac disease without limitations of physical activity. Ordinary physical activity caused no undue fatigue, palpitation, dyspnea or angina pain. Class II: cardiac disease with slight limitation of physical activity, comfortable at rest. Ordinary physical activity resulted in fatigue, palpitation, dyspnea or angina pain. Class III: cardiac disease with marked limitation of physical activity, comfortable at rest. Less than ordinary physical activity caused fatigue, palpitation, dyspnea or angina pain. Class IV: cardiac disease with inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or angina syndrome might be present even at rest. If any physical activity was undertaken, discomfort was increased. Participants with change from baseline were classified as improved (shifted from higher to lower class), unchanged (no change in class) or worsened (shifted from lower to higher class).

    Time frame: Baseline, Month 12

  5. Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Month 60

    NYHA classified participants in 4 classes: Class I: cardiac disease without limitations of physical activity. Ordinary physical activity caused no undue fatigue, palpitation, dyspnea or angina pain. Class II: cardiac disease with slight limitation of physical activity, comfortable at rest. Ordinary physical activity resulted in fatigue, palpitation, dyspnea or angina pain. Class III: cardiac disease with marked limitation of physical activity, comfortable at rest. Less than ordinary physical activity caused fatigue, palpitation, dyspnea or angina pain. Class IV: cardiac disease with inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or angina syndrome might be present even at rest. If any physical activity was undertaken, discomfort was increased. Participants with change from baseline were classified as improved (shifted from higher to lower class), unchanged (no change in class) or worsened (shifted from lower to higher class).

    Time frame: Baseline, Month 60

  6. Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 12

    6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, the total distance that a participant could walk in 6 minutes was evaluated.

    Time frame: Baseline, Month 12

  7. Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 60

    6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, the total distance that a participant could walk in 6 minutes was evaluated.

    Time frame: Baseline, Month 60

  8. Number of Participants Categorized Based on Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 12

    6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants were categorized based on the total distance walked as Level 1 = total distance walked less than (\<) 300 meter; Level 2 = total distance walked between 300 to 374.9 meter; Level 3 = total distance walked between 375 to 449.9 meter; Level 4 = total distance walked greater than or equal to (\>=) 450 meter.

    Time frame: Month 12

  9. Number of Participants Categorized Based on Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 60

    6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants were categorized based on the total distance walked as Level 1 = total distance walked \< 300 meter; Level 2 = total distance walked between 300 to 374.9 meter; Level 3 = total distance walked between 375 to 449.9 meter; Level 4 = total distance walked \>=450 meter.

    Time frame: Month 60

  10. Change From Baseline in Dyspnea and Fatigue Scores During 6 Minute Walk Test (6MWT) at Month 12

    6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. Dyspnea: participants were asked to rate the difficulty of their breathing, pre-walk and post-walk at each visit, on a scale of range 0 (no breathlessness at all) to 10 (maximum breathlessness). Higher scores indicated more severity. Fatigue: participants were asked to rate the how tired they felt, pre-walk and post-walk at each visit, on a scale of range 0 (not at all) to 10 (maximal) Higher scores indicated more fatigue. At each visit, scores for pre-walk test, post-walk test and within visit difference (difference from post-walk to pre-walk) were evaluated. Change from baseline was calculated for each pre-walk test, post-walk test and within visit difference at Month 12.

    Time frame: Baseline, Month 12

  11. Change From Baseline in Dyspnea and Fatigue Scores During 6 Minute Walk Test (6MWT) at Month 60

    6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. Dyspnea: participants were asked to rate the difficulty of their breathing, pre-walk and post-walk at each visit, on a scale of range 0 (no breathlessness at all) to 10 (maximum breathlessness). Higher scores indicated more severity. Fatigue: participants were asked to rate the how tired they felt, pre-walk and post-walk at each visit, on a scale of range 0 (not at all) to 10 (maximal) Higher scores indicated more fatigue. At each visit, scores for pre-walk test, post-walk test and within visit difference (difference from post-walk to pre-walk) were evaluated. Change from baseline was calculated for each pre-walk test, post-walk test and within visit difference at Month 60.

    Time frame: Baseline, Month 60

  12. Number of Participants Categorized on Basis of Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 12

    6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants on basis of change from baseline in total distance walked were categorized as worsened, unchanged or improved. If distance walked at a visit was greater than distance walked at baseline, then categorized as 'improved'. If distance walked at a visit was equal to distance walked at baseline, then categorized as 'unchanged'. If distance walked at a visit was less than distance walked at baseline, then categorized as 'worsened'.

    Time frame: Baseline, Month 12

  13. Number of Participants Categorized on Basis of Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 60

    6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants on basis of change from baseline in total distance walked were categorized as worsened, unchanged or improved. If distance walked at a visit was greater than distance walked at baseline, then categorized as 'improved'. If distance walked at a visit was equal to distance walked at baseline, then categorized as 'unchanged'. If distance walked at a visit was less than distance walked at baseline, then categorized as 'worsened'.

    Time frame: Baseline, Month 60

  14. Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Summary Score at Month 12

    KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: physical limitation, social limitation, quality of life, self-efficacy, symptom stability, symptom frequency, symptom burden, and total symptoms (calculated as the mean of symptom frequency and symptom burden scores). Two summary scores were calculated: clinical summary (calculated as mean of physical limitation and total symptom scores) and overall summary (calculated as mean of physical limitation, social limitation, total symptoms, and quality of life scores). Each domain and both summary scores were scaled to range from 0 (worse health status) to 100 (best health status); higher scores represented better health status.

    Time frame: Baseline, Month 12

  15. Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Summary Score at Month 60

    KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: physical limitation, social limitation, quality of life, self-efficacy, symptom stability, symptom frequency, symptom burden, and total symptoms (calculated as the mean of symptom frequency and symptom burden scores). Two summary scores were calculated: clinical summary (calculated as mean of physical limitation and total symptom scores) and overall summary (calculated as mean of physical limitation, social limitation, total symptoms, and quality of life scores). Each domain and both summary scores were scaled to range from 0 (worse health status) to 100 (best health status); higher scores represented better health status.

    Time frame: Baseline, Month 60

  16. Change From Baseline in Troponin I and Troponin T Serum Levels at Month 12

    Troponin I and troponin T are the cardiac markers. Troponin I and troponin T are part of the troponin complex, where troponin I is bound to actin in thin myofilaments and troponin T is bound to tropomyosin. Higher level of these markers is indicative of heart damage.

    Time frame: Baseline, Month 12

  17. Change From Baseline in Troponin I and Troponin T Serum Levels at Month 60

    Troponin I and troponin T are the cardiac markers. Troponin I and troponin T are part of the troponin complex, where troponin I is bound to actin in thin myofilaments and troponin T is bound to tropomyosin. Higher level of these markers is indicative of heart damage.

    Time frame: Baseline, Month 60

  18. Change From Baseline in Amino-Terminal B-type Natriuretic Peptide (NT-proBNP) Serum Level at Month 12

    NT-proBNP is biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ left ventricular \[LV\] wall stress).

    Time frame: Baseline, Month 12

  19. Change From Baseline in Serum Levels of Amino-Terminal B-type Natriuretic Peptide (NT-proBNP) at Month 60

    NT-proBNP is biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ LV wall stress).

    Time frame: Baseline, Month 60

Secondary outcomes

  1. Percentage of Participants With Categories of Patient Global Assessment (PGA) for Follow-up Visit: Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126 and 132

    Participants overall quality of life was measured by PGA. At each follow-up visit, participants were asked, "How do you feel today as compared to when we talked with you at your last clinic visit for this study?" and participants responded to any of the following: markedly improved, moderately improved, mildly improved, unchanged, mildly worsened, moderately worsened or markedly worsened.

    Time frame: Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126, 132

  2. Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126 and 132

    NYHA classified participants in 4 classes: Class I: cardiac disease without limitations of physical activity. Ordinary physical activity caused no undue fatigue, palpitation, dyspnea or angina pain. Class II: cardiac disease with slight limitation of physical activity, comfortable at rest. Ordinary physical activity resulted in fatigue, palpitation, dyspnea or angina pain. Class III: cardiac disease with marked limitation of physical activity, comfortable at rest. Less than ordinary physical activity caused fatigue, palpitation, dyspnea or angina pain. Class IV: cardiac disease with inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or angina syndrome might be present even at rest. If any physical activity was undertaken, discomfort was increased. Participants with change from baseline were classified as improved (shifted from higher to lower class), unchanged (no change in class) or worsened (shifted from lower to higher class).

    Time frame: Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126, 132

  3. Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 132

    6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, the total distance that a participant could walk in 6 minutes was evaluated.

    Time frame: Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 132

  4. Number of Participants Categorized Based on Total Distance Walked During 6 Minute Walk Test (6MWT) at Baseline, Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126 and 132

    6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants were categorized based on the total distance walked as Level 1 = total distance walked \< 300 meter; Level 2 = total distance walked between 300 to 374.9 meter; Level 3 = total distance walked between 375 to 449.9 meter; Level 4 = total distance walked \>=450 meter.

    Time frame: Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126, 132

  5. Change From Baseline in Dyspnea and Fatigue Scores During 6 Minute Walk Test (6MWT) at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 132

    6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. Dyspnea: participants were asked to rate the difficulty of their breathing, pre-walk and post-walk at each visit, on a scale of range 0 (no breathlessness at all) to 10 (maximum breathlessness). Higher scores indicated more severity. Fatigue: participants were asked to rate the how tired they felt, pre-walk and post-walk at each visit, on a scale of range 0 (not at all) to 10 (maximal) Higher scores indicated more fatigue. At each visit, scores for pre-walk test, post-walk test and within visit difference (difference from post-walk to pre-walk) were evaluated. Change from baseline was calculated for each pre-walk test, post-walk test and within visit difference at specified visits.

    Time frame: Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 132

  6. Number of Participants Categorized on Basis of Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 132

    6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants on basis of change from baseline in total distance walked were categorized as worsened, unchanged or improved. If distance walked at a visit was greater than distance walked at baseline, then categorized as 'improved'. If distance walked at a visit was equal to distance walked at baseline, then categorized as 'unchanged'. If distance walked at a visit was less than distance walked at baseline, then categorized as 'worsened'.

    Time frame: Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 132

  7. Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Summary Score at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126 and 132

    KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: physical limitation, social limitation, quality of life, self-efficacy, symptom stability, symptom frequency, symptom burden, and total symptoms (calculated as the mean of symptom frequency and symptom burden scores). Two summary scores were calculated: clinical summary (calculated as mean of physical limitation and total symptom scores) and overall summary (calculated as mean of physical limitation, social limitation, total symptoms, and quality of life scores). Each domain and both summary scores were scaled to range from 0 (worse health status) to 100 (best health status); higher scores represented better health status.

    Time frame: Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126, 132

  8. Number of Participants With Abnormalities in Echocardiography

    Echocardiography abnormalities included: absent respiratory variation of inferior vena cava, any valve thickening, aortic valve thickening, decreased respiratory variation of inferior vena cava, dilated inferior vena cava, E deceleration time less than or equal to (\<=) 150 millisecond, E wave/A Wave (E/A) ratio \>=2, ejection fraction \< 50%, isovolumic relaxation time (IVRT) \<=70 millisecond, left ventricular posterior wall thickness \>=13 millimeter (mm), left ventricular septal thickness \>= 13 mm, mitral valve thickening, pericardial effusion, pulmonary valve thickening, right ventricular thickness \>=7 mm, tricuspid valve thickening, ratio between early mitral inflow velocity and mitral annular early diastolic velocity (e/e') Lateral greater than (\>) 15, e/e' Septal \>15.

    Time frame: Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303

  9. Change From Baseline in Troponin I and Troponin T Serum Levels at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 126

    Troponin I and troponin T are the cardiac markers. Troponin I and troponin T are part of the troponin complex, where troponin I is bound to actin in thin myofilaments and troponin T is bound to tropomyosin. Higher level of these markers is indicative of heart damage.

    Time frame: Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 126

  10. Change From Baseline in Amino-Terminal B-type Natriuretic Peptide (NT-proBNP) Serum Level at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 126

    NT-proBNP was biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ LV wall stress).

    Time frame: Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126

  11. Number of Participants With All-cause Hospitalization and Cardiac-related Hospitalization Events

    All cause hospitalization was defined as any serious adverse event, which resulted in hospitalization. Cardiac-related hospitalization was any hospitalization meeting the following criteria: cardiac disorders or AE preferred term as chest discomfort, chest pain, death, cerebrovascular accident, embolic stroke, disease progression.

    Time frame: Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303

  12. Time to All-cause Mortality and Cardiac-Related Mortality

    Time to death for all participants with a death date in Clinical Database, or censored at the last dose date + 28 days for those participants who were alive at the end of the study is reported.

    Time frame: Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303

  13. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and all non-serious adverse events.

    Time frame: Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303

  14. Number of Participants With Treatment-Related Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and all non-serious adverse events. Relatedness to study drug was assessed by the investigator as (Yes/No).

    Time frame: Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303

  15. Number of Participants With Clinically Significant Physical Examination Findings

    Physical examination included examination of general appearance, endocrine, head and neck, cardiovascular, eyes, abdomen, ears, skin, nose, musculoskeletal, throat, neurological, respiratory, immunologic/allergies, genitourinary, hematologic/lymphatic. Clinical significance of any physical examination finding was judged by investigator.

    Time frame: Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303

  16. Number of Participants With Any Concomitant Medications

    Number of participants who used medication other than study drug were reported.

    Time frame: Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303

  17. Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings

    ECG parameters included PR interval (millisecond), RR interval (millisecond), QRS interval (millisecond), QT and QTc interval (millisecond) and heart rate (beats per minute). Clinical significance of any ECG finding was judged by investigator.

    Time frame: Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303

  18. Number of Participants With Laboratory Abnormalities

    Laboratory parameters included hematology and biochemistry: alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen, gamma glutamyl transferase (GGT), creatinine, total bilirubin, international normalized ratio (INR), troponin I, troponin T, prothrombin time, sodium, globulin potassium, chloride, bicarbonate, cholesterol, calcium, uric acid, inorganic phosphorous, thyroid-stimulating hormone, glucose, total thyroxine (T4), free T4, total proteins, prealbumin (transthyretin), albumin, hemoglobin, platelets, hematocrit, white blood cell count, red blood cell count, neutrophils, packed cell volume, lymphocytes, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, eosinophils, mean corpuscular hemoglobin concentration, basophils, retinol-binding protein, Urinalysis: bilirubin, pH, blood (free Hb), protein, nitrite, glucose, urobilinogen, ketones, specific gravity.

    Time frame: Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303

07

Results

Posted Jan 5, 2021

Participant flow

Participants with transthyretin amyloid cardiomyopathy (TTR-CM/ATTR-CM), who had not undergone liver or heart transplantation and who had completed previous study Fx1B-201 (NCT00694161) were eligible to enter this current study Fx1B-303 (NCT00935012).

Participant flow — Overall Study
MilestoneTafamidis 20 mg
Started31
Completed2
Not completed29
Withdrew: Death19
Withdrew: Withdrawal by subject3
Withdrew: Other5
Withdrew: Adverse event2

Outcome measures

PrimaryPercentage of Participants With Categories of Patient Global Assessment (PGA) for Follow-up Visit: Month 12

Participants overall quality of life was measured by PGA. At follow-up visit, participants were asked, "How do you feel today as compared to when we talked with you at your last clinic visit for this study?" and participants responded to any of the following: markedly improved, moderately improved, mildly improved, unchanged, mildly worsened, moderately worsened or markedly worsened.

Time frame:
Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With Categories of Patient Global Assessment (PGA) for Follow-up Visit: Month 12
percentage of participantsTafamidis 20 mg
Markedly Improved0 (0.0 to 11.2)
Moderately Improved16.1 (5.5 to 33.7)
Mildly Improved9.7 (2.0 to 25.8)
Unchanged51.6 (33.1 to 69.8)
Mildly Worsened12.9 (3.6 to 29.8)
Moderately Worsened9.7 (2.0 to 25.8)
Markedly Worsened0 (0.0 to 11.2)
PrimaryPercentage of Participants With Categories of Patient Global Assessment (PGA) for Follow-up Visit: Month 60

Participants overall quality of life was measured by PGA. At follow-up visit, participants were asked, "How do you feel today as compared to when we talked with you at your last clinic visit for this study?" and participants responded to any of the following: markedly improved, moderately improved, mildly improved, unchanged, mildly worsened, moderately worsened or markedly worsened.

Time frame:
Month 60
Reported as:
Number · percentage of participants
Percentage of Participants With Categories of Patient Global Assessment (PGA) for Follow-up Visit: Month 60
percentage of participantsTafamidis 20 mg
Markedly Improved0 (0.0 to 26.5)
Moderately Improved8.3 (0.2 to 38.5)
Mildly Improved8.3 (0.2 to 38.5)
Unchanged50.0 (21.1 to 78.9)
Mildly Worsened16.7 (2.1 to 48.4)
Moderately Worsened16.7 (2.1 to 48.4)
Markedly Worsened0 (0.0 to 26.5)
PrimaryNumber of Participants Classified on the Basis of New York Heart Association (NYHA) Classification at Baseline

NYHA classified participants in 4 classes. Class I included participants with cardiac disease without limitations of physical activity. Ordinary physical activity did not cause undue fatigue, palpitation, dyspnea, or anginal pain. Class II included participants with cardiac disease with slight limitation of physical activity. They were comfortable at rest. Ordinary physical activity resulted in fatigue, palpitation, dyspnea, or anginal pain. Class III included participants with cardiac disease with marked limitation of physical activity. They were comfortable at rest. Less than ordinary physical activity caused fatigue, palpitation, dyspnea, or anginal pain. Class IV included participants with cardiac disease with the inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome might be present even at rest. If any physical activity was undertaken, discomfort was increased.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Number of Participants Classified on the Basis of New York Heart Association (NYHA) Classification at Baseline
ParticipantsTafamidis 20 mg
CLASS I4
CLASS II26
CLASS III1
CLASS IV0
PrimaryNumber of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Month 12

NYHA classified participants in 4 classes: Class I: cardiac disease without limitations of physical activity. Ordinary physical activity caused no undue fatigue, palpitation, dyspnea or angina pain. Class II: cardiac disease with slight limitation of physical activity, comfortable at rest. Ordinary physical activity resulted in fatigue, palpitation, dyspnea or angina pain. Class III: cardiac disease with marked limitation of physical activity, comfortable at rest. Less than ordinary physical activity caused fatigue, palpitation, dyspnea or angina pain. Class IV: cardiac disease with inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or angina syndrome might be present even at rest. If any physical activity was undertaken, discomfort was increased. Participants with change from baseline were classified as improved (shifted from higher to lower class), unchanged (no change in class) or worsened (shifted from lower to higher class).

Time frame:
Baseline, Month 12
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Month 12
ParticipantsTafamidis 20 mg
Worsened7
Unchanged20
Improved4
PrimaryNumber of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Month 60

NYHA classified participants in 4 classes: Class I: cardiac disease without limitations of physical activity. Ordinary physical activity caused no undue fatigue, palpitation, dyspnea or angina pain. Class II: cardiac disease with slight limitation of physical activity, comfortable at rest. Ordinary physical activity resulted in fatigue, palpitation, dyspnea or angina pain. Class III: cardiac disease with marked limitation of physical activity, comfortable at rest. Less than ordinary physical activity caused fatigue, palpitation, dyspnea or angina pain. Class IV: cardiac disease with inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or angina syndrome might be present even at rest. If any physical activity was undertaken, discomfort was increased. Participants with change from baseline were classified as improved (shifted from higher to lower class), unchanged (no change in class) or worsened (shifted from lower to higher class).

Time frame:
Baseline, Month 60
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Month 60
ParticipantsTafamidis 20 mg
Worsened8
Unchanged3
Improved1
PrimaryChange From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 12

6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, the total distance that a participant could walk in 6 minutes was evaluated.

Time frame:
Baseline, Month 12
Reported as:
Mean · meters
Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 12
metersTafamidis 20 mg
Baseline363.7 ± 130.80
Change at Month 12-11.2 ± 76.39
PrimaryChange From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 60

6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, the total distance that a participant could walk in 6 minutes was evaluated.

Time frame:
Baseline, Month 60
Reported as:
Mean · meters
Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 60
metersTafamidis 20 mg
Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 60-121.4 ± 145.82
PrimaryNumber of Participants Categorized Based on Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 12

6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants were categorized based on the total distance walked as Level 1 = total distance walked less than (\<) 300 meter; Level 2 = total distance walked between 300 to 374.9 meter; Level 3 = total distance walked between 375 to 449.9 meter; Level 4 = total distance walked greater than or equal to (\>=) 450 meter.

Time frame:
Month 12
Reported as:
Count of participants · Participants
Number of Participants Categorized Based on Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 12
ParticipantsTafamidis 20 mg
Level 18
Level 27
Level 37
Level 46
PrimaryNumber of Participants Categorized Based on Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 60

6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants were categorized based on the total distance walked as Level 1 = total distance walked \< 300 meter; Level 2 = total distance walked between 300 to 374.9 meter; Level 3 = total distance walked between 375 to 449.9 meter; Level 4 = total distance walked \>=450 meter.

Time frame:
Month 60
Reported as:
Count of participants · Participants
Number of Participants Categorized Based on Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 60
ParticipantsTafamidis 20 mg
Level 14
Level 23
Level 30
Level 41
PrimaryChange From Baseline in Dyspnea and Fatigue Scores During 6 Minute Walk Test (6MWT) at Month 12

6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. Dyspnea: participants were asked to rate the difficulty of their breathing, pre-walk and post-walk at each visit, on a scale of range 0 (no breathlessness at all) to 10 (maximum breathlessness). Higher scores indicated more severity. Fatigue: participants were asked to rate the how tired they felt, pre-walk and post-walk at each visit, on a scale of range 0 (not at all) to 10 (maximal) Higher scores indicated more fatigue. At each visit, scores for pre-walk test, post-walk test and within visit difference (difference from post-walk to pre-walk) were evaluated. Change from baseline was calculated for each pre-walk test, post-walk test and within visit difference at Month 12.

Time frame:
Baseline, Month 12
Reported as:
Mean · units on a scale
Change From Baseline in Dyspnea and Fatigue Scores During 6 Minute Walk Test (6MWT) at Month 12
units on a scaleTafamidis 20 mg
Dyspnea: Baseline, Pre walk0.6 ± 0.72
Dyspnea: Baseline, Post walk2.5 ± 1.94
Dyspnea: Baseline, Within Visit Difference1.9 ± 1.94
Dyspnea: Change at Month 12, Pre walk0.6 ± 1.61
Dyspnea: Change at Month 12, Post walk1.2 ± 1.60
Dyspnea:Change at Month 12,Within Visit Difference0.6 ± 1.70
Fatigue: Baseline, Pre-walk0.9 ± 1.27
Fatigue: Baseline, Post-walk2.4 ± 2.06
Fatigue: Baseline, Within Visit Difference1.4 ± 2.51
Fatigue: Change at Month 12, Pre Walk0.5 ± 2.20
Fatigue: Change at Month 12, Post-Walk0.9 ± 1.98
Fatigue:Change at Month 12,Within Visit Difference0.4 ± 2.20
PrimaryChange From Baseline in Dyspnea and Fatigue Scores During 6 Minute Walk Test (6MWT) at Month 60

6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. Dyspnea: participants were asked to rate the difficulty of their breathing, pre-walk and post-walk at each visit, on a scale of range 0 (no breathlessness at all) to 10 (maximum breathlessness). Higher scores indicated more severity. Fatigue: participants were asked to rate the how tired they felt, pre-walk and post-walk at each visit, on a scale of range 0 (not at all) to 10 (maximal) Higher scores indicated more fatigue. At each visit, scores for pre-walk test, post-walk test and within visit difference (difference from post-walk to pre-walk) were evaluated. Change from baseline was calculated for each pre-walk test, post-walk test and within visit difference at Month 60.

Time frame:
Baseline, Month 60
Reported as:
Mean · units on a scale
Change From Baseline in Dyspnea and Fatigue Scores During 6 Minute Walk Test (6MWT) at Month 60
units on a scaleTafamidis 20 mg
Dyspnea: Change at Month 60, Pre walk0.8 ± 1.41
Dyspnea: Change at Month 60, Post walk0.8 ± 1.60
Dyspnea:Change at Month 60,Within Visit Difference0.1 ± 1.94
Fatigue: Change at Month 60, Pre walk0.1 ± 0.35
Fatigue: Change at Month 60, Post walk0.4 ± 1.51
Fatigue:Change at Month 60,Within Visit Difference0.3 ± 1.49
PrimaryNumber of Participants Categorized on Basis of Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 12

6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants on basis of change from baseline in total distance walked were categorized as worsened, unchanged or improved. If distance walked at a visit was greater than distance walked at baseline, then categorized as 'improved'. If distance walked at a visit was equal to distance walked at baseline, then categorized as 'unchanged'. If distance walked at a visit was less than distance walked at baseline, then categorized as 'worsened'.

Time frame:
Baseline, Month 12
Reported as:
Count of participants · Participants
Number of Participants Categorized on Basis of Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 12
ParticipantsTafamidis 20 mg
Worsened7
Unchanged16
Improved5
PrimaryNumber of Participants Categorized on Basis of Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 60

6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants on basis of change from baseline in total distance walked were categorized as worsened, unchanged or improved. If distance walked at a visit was greater than distance walked at baseline, then categorized as 'improved'. If distance walked at a visit was equal to distance walked at baseline, then categorized as 'unchanged'. If distance walked at a visit was less than distance walked at baseline, then categorized as 'worsened'.

Time frame:
Baseline, Month 60
Reported as:
Count of participants · Participants
Number of Participants Categorized on Basis of Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 60
ParticipantsTafamidis 20 mg
Worsened5
Unchanged3
Improved0
PrimaryChange From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Summary Score at Month 12

KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: physical limitation, social limitation, quality of life, self-efficacy, symptom stability, symptom frequency, symptom burden, and total symptoms (calculated as the mean of symptom frequency and symptom burden scores). Two summary scores were calculated: clinical summary (calculated as mean of physical limitation and total symptom scores) and overall summary (calculated as mean of physical limitation, social limitation, total symptoms, and quality of life scores). Each domain and both summary scores were scaled to range from 0 (worse health status) to 100 (best health status); higher scores represented better health status.

Time frame:
Baseline, Month 12
Reported as:
Mean · units on a scale
Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Summary Score at Month 12
units on a scaleTafamidis 20 mg
Overall Summary Score: Baseline72.21 ± 18.974
Overall Summary Score: Change at Month 12-4.54 ± 12.724
Clinical Summary Score: Baseline74.79 ± 19.296
Clinical Summary Score: Change at Month 12-5.60 ± 13.792
PrimaryChange From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Summary Score at Month 60

KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: physical limitation, social limitation, quality of life, self-efficacy, symptom stability, symptom frequency, symptom burden, and total symptoms (calculated as the mean of symptom frequency and symptom burden scores). Two summary scores were calculated: clinical summary (calculated as mean of physical limitation and total symptom scores) and overall summary (calculated as mean of physical limitation, social limitation, total symptoms, and quality of life scores). Each domain and both summary scores were scaled to range from 0 (worse health status) to 100 (best health status); higher scores represented better health status.

Time frame:
Baseline, Month 60
Reported as:
Mean · units on a scale
Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Summary Score at Month 60
units on a scaleTafamidis 20 mg
Overall Summary Score: Change at Month 60-12.93 ± 29.306
Clinical Summary Score: Change at Month 60-18.12 ± 29.432
PrimaryChange From Baseline in Troponin I and Troponin T Serum Levels at Month 12

Troponin I and troponin T are the cardiac markers. Troponin I and troponin T are part of the troponin complex, where troponin I is bound to actin in thin myofilaments and troponin T is bound to tropomyosin. Higher level of these markers is indicative of heart damage.

Time frame:
Baseline, Month 12
Reported as:
Mean · nanogram per milliliter
Change From Baseline in Troponin I and Troponin T Serum Levels at Month 12
nanogram per milliliterTafamidis 20 mg
Troponin I: Baseline0.132 ± 0.0627
Troponin I: Change at Month 120.016 ± 0.0652
Troponin T: Baseline0.0448 ± 0.03402
Troponin T: Change at Month 120.0110 ± 0.02239
PrimaryChange From Baseline in Troponin I and Troponin T Serum Levels at Month 60

Troponin I and troponin T are the cardiac markers. Troponin I and troponin T are part of the troponin complex, where troponin I is bound to actin in thin myofilaments and troponin T is bound to tropomyosin. Higher level of these markers is indicative of heart damage.

Time frame:
Baseline, Month 60
Reported as:
Mean · nanogram per milliliter
Change From Baseline in Troponin I and Troponin T Serum Levels at Month 60
nanogram per milliliterTafamidis 20 mg
Troponin T: Change at Month 600.026 ± 0.0937
Troponin I: Change at Month 600.0810 ± 0.17779
PrimaryChange From Baseline in Amino-Terminal B-type Natriuretic Peptide (NT-proBNP) Serum Level at Month 12

NT-proBNP is biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ left ventricular \[LV\] wall stress).

Time frame:
Baseline, Month 12
Reported as:
Mean · nanogram per milliliter
Change From Baseline in Amino-Terminal B-type Natriuretic Peptide (NT-proBNP) Serum Level at Month 12
nanogram per milliliterTafamidis 20 mg
Baseline4526.1 ± 3814.21
Change at Month 12818.3 ± 3133.86
PrimaryChange From Baseline in Serum Levels of Amino-Terminal B-type Natriuretic Peptide (NT-proBNP) at Month 60

NT-proBNP is biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ LV wall stress).

Time frame:
Baseline, Month 60
Reported as:
Mean · nanogram per milliliter
Change From Baseline in Serum Levels of Amino-Terminal B-type Natriuretic Peptide (NT-proBNP) at Month 60
nanogram per milliliterTafamidis 20 mg
Change From Baseline in Serum Levels of Amino-Terminal B-type Natriuretic Peptide (NT-proBNP) at Month 605127.6 ± 10598.94
SecondaryPercentage of Participants With Categories of Patient Global Assessment (PGA) for Follow-up Visit: Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126 and 132

Participants overall quality of life was measured by PGA. At each follow-up visit, participants were asked, "How do you feel today as compared to when we talked with you at your last clinic visit for this study?" and participants responded to any of the following: markedly improved, moderately improved, mildly improved, unchanged, mildly worsened, moderately worsened or markedly worsened.

Time frame:
Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126, 132
Reported as:
Number · percentage of participants
Percentage of Participants With Categories of Patient Global Assessment (PGA) for Follow-up Visit: Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126 and 132
percentage of participantsTafamidis 20 mg
Month 6: Markedly Improved9.7 (2.0 to 25.8)
Month 6: Moderately Improved3.2 (0.1 to 16.7)
Month 6: Mildly Improved9.7 (2.0 to 25.8)
Month 6: Unchanged51.6 (33.1 to 69.8)
Month 6: Mildly Worsened25.8 (11.9 to 44.6)
Month 6: Moderately Worsened0 (0.0 to 11.2)
Month 6: Markedly Worsened0 (0.0 to 11.2)
Month 18: Markedly Improved7.1 (0.9 to 23.5)
Month 18: Moderately Improved10.7 (2.3 to 28.2)
Month 18: Mildly Improved17.9 (6.1 to 36.9)
Month 18: Unchanged25.0 (10.7 to 44.9)
Month 18: Mildly Worsened17.9 (6.1 to 36.9)
Month 18: Moderately Worsened10.7 (2.3 to 28.2)
Month 18: Markedly Worsened10.7 (2.3 to 28.2)
Month 24: Markedly Improved9.1 (1.1 to 29.2)
Month 24: Moderately Improved18.2 (5.2 to 40.3)
Month 24: Mildly Improved13.6 (2.9 to 34.9)
Month 24: Unchanged27.3 (10.7 to 50.2)
Month 24: Mildly Worsened22.7 (7.8 to 45.4)
Month 24: Moderately Worsened4.5 (0.1 to 22.8)
Month 24: Markedly Worsened4.5 (0.1 to 22.8)
Month 30: Markedly Improved0 (0.0 to 16.8)
Month 30: Moderately Improved10.0 (1.2 to 31.7)
Month 30: Mildly Improved5.0 (0.1 to 24.9)
Month 30: Unchanged40.0 (19.1 to 63.9)
Month 30: Mildly Worsened25.0 (8.7 to 49.1)
Month 30: Moderately Worsened20.0 (5.7 to 43.7)
Month 30: Markedly Worsened0 (0.0 to 16.8)
Month 36: Markedly Improved0 (0.0 to 17.6)
Month 36: Moderately Improved0 (0.0 to 17.6)
Month 36: Mildly Improved5.3 (0.1 to 26.0)
Month 36: Unchanged47.4 (24.4 to 71.1)
Month 36: Mildly Worsened26.3 (9.1 to 51.2)
Month 36: Moderately Worsened21.1 (6.1 to 45.6)
Month 36: Markedly Worsened0 (0.0 to 17.6)
Month 42: Markedly Improved0 (0.0 to 19.5)
Month 42: Moderately Improved0 (0.0 to 19.5)
Month 42: Mildly Improved0 (0.0 to 19.5)
Month 42: Unchanged29.4 (10.3 to 56.0)
Month 42: Mildly Worsened35.3 (14.2 to 61.7)
Month 42: Moderately Worsened11.8 (1.5 to 36.4)
Month 42: Markedly Worsened23.5 (6.8 to 49.9)
Month 48: Markedly Improved0 (0.0 to 24.7)
Month 48: Moderately Improved0 (0.0 to 24.7)
Month 48: Mildly Improved23.1 (5.0 to 53.8)
Month 48: Unchanged53.8 (25.1 to 80.8)
Month 48: Mildly Worsened15.4 (1.9 to 45.4)
Month 48: Moderately Worsened7.7 (0.2 to 36.0)
Month 48: Markedly Worsened0 (0.0 to 24.7)
Month 54: Markedly Improved0 (0.0 to 24.7)
Month 54: Moderately Improved7.7 (0.2 to 36.0)
Month 54: Mildly Improved0 (0.0 to 24.7)
Month 54: Unchanged61.5 (31.6 to 86.1)
Month 54: Mildly Worsened23.1 (5.0 to 53.8)
Month 54: Moderately Worsened7.7 (0.2 to 36.0)
Month 54: Markedly Worsened0 (0.0 to 24.7)
Month 66: Markedly Improved16.7 (0.4 to 64.1)
Month 66: Moderately Improved0 (0.0 to 45.9)
Month 66: Mildly Improved0 (0.0 to 45.9)
Month 66: Unchanged50.0 (11.8 to 88.2)
Month 66: Mildly Worsened0 (0.0 to 45.9)
Month 66: Moderately Worsened33.3 (4.3 to 77.7)
Month 66: Markedly Worsened0 (0.0 to 45.9)
Month 72: Markedly Improved0 (0.0 to 41.0)
Month 72: Moderately Improved0 (0.0 to 41.0)
Month 72: Mildly Improved0 (0.0 to 41.0)
Month 72: Unchanged71.4 (29.0 to 96.3)
Month 72: Mildly Worsened28.6 (3.7 to 71.0)
Month 72: Moderately Worsened0 (0.0 to 41.0)
Month 72: Markedly Worsened0 (0.0 to 41.0)
Month 78: Markedly Improved14.3 (0.4 to 57.9)
Month 78: Moderately Improved0 (0.0 to 41.0)
Month 78: Mildly Improved0 (0.0 to 41.0)
Month 78: Unchanged28.6 (3.7 to 71.0)
Month 78: Mildly Worsened28.6 (3.7 to 71.0)
Month 78: Moderately Worsened28.6 (3.7 to 71.0)
Month 78: Markedly Worsened0 (0.0 to 41.0)
Month 84: Markedly Improved16.7 (0.4 to 64.1)
Month 84: Moderately Improved0 (0.0 to 45.9)
Month 84: Mildly Improved0 (0.0 to 45.9)
Month 84: Unchanged33.3 (4.3 to 77.7)
Month 84: Mildly Worsened16.7 (0.4 to 64.1)
Month 84: Moderately Worsened16.7 (0.4 to 64.1)
Month 84: Markedly Worsened16.7 (0.4 to 64.1)
Month 90: Markedly Improved0 (0.0 to 41.0)
Month 90: Moderately Improved0 (0.0 to 41.0)
Month 90: Mildly Improved42.9 (9.9 to 81.6)
Month 90: Unchanged28.6 (3.7 to 71.0)
Month 90: Mildly Worsened28.6 (3.7 to 71.0)
Month 90: Moderately Worsened0 (0.0 to 41.0)
Month 90: Markedly Worsened0 (0.0 to 41.0)
Month 96: Markedly Improved0 (0.0 to 60.2)
Month 96: Moderately Improved0 (0.0 to 60.2)
Month 96: Mildly Improved0 (0.0 to 60.2)
Month 96: Unchanged25.0 (0.6 to 80.6)
Month 96: Mildly Worsened50.0 (6.8 to 93.2)
Month 96: Moderately Worsened25.0 (0.6 to 80.6)
Month 96: Markedly Worsened0 (0.0 to 60.2)
Month 102: Markedly Improved0 (0.0 to 60.2)
Month 102: Moderately Improved0 (0.0 to 60.2)
Month 102: Mildly Improved0 (0.0 to 60.2)
Month 102: Unchanged75.0 (19.4 to 99.4)
Month 102: Mildly Worsened0 (0.0 to 60.2)
Month 102: Moderately Worsened0 (0.0 to 60.2)
Month 102: Markedly Worsened25.0 (0.6 to 80.6)
Month 108: Markedly Improved40.0 (5.3 to 85.3)
Month 108: Moderately Improved0 (0.0 to 52.2)
Month 108: Mildly Improved20.0 (0.5 to 71.6)
Month 108: Unchanged40.0 (5.3 to 85.3)
Month 108: Mildly Worsened0 (0.0 to 52.2)
Month 108: Moderately Worsened0 (0.0 to 52.2)
Month 108: Markedly Worsened0 (0.0 to 52.2)
Month 114: Markedly Improved0 (0.0 to 60.2)
Month 114: Moderately Improved0 (0.0 to 60.2)
Month 114: Mildly Improved25.0 (0.6 to 80.6)
Month 114: Unchanged0 (0.0 to 60.2)
Month 114: Mildly Worsened75.0 (19.4 to 99.4)
Month 114: Moderately Worsened0 (0.0 to 60.2)
Month 114: Markedly Worsened0 (0.0 to 60.2)
Month 120: Markedly Improved0 (0.0 to 84.2)
Month 120: Moderately Improved0 (0.0 to 84.2)
Month 120: Mildly Improved50.0 (1.3 to 98.7)
Month 120: Unchanged50.0 (1.3 to 98.7)
Month 120: Mildly Worsened0 (0.0 to 84.2)
Month 120: Moderately Worsened0 (0.0 to 84.2)
Month 120: Markedly Worsened0 (0.0 to 84.2)
Month 126: Markedly Improved0 (0.0 to 84.2)
Month 126: Moderately Improved0 (0.0 to 84.2)
Month 126: Mildly Improved0 (0.0 to 84.2)
Month 126: Unchanged0 (0.0 to 84.2)
Month 126: Mildly Worsened100.0 (15.8 to 100.0)
Month 126: Moderately Worsened0 (0.0 to 84.2)
Month 126: Markedly Worsened0 (0.0 to 84.2)
Month 132: Markedly Improved0 (0.0 to 97.5)
Month 132: Moderately Improved0 (0.0 to 97.5)
Month 132: Mildly Improved0 (0.0 to 97.5)
Month 132: Unchanged0 (0.0 to 97.5)
Month 132: Mildly Worsened100.0 (2.5 to 100.0)
Month 132: Moderately Worsened0 (0.0 to 97.5)
Month 132: Markedly Worsened0 (0.0 to 97.5)
SecondaryNumber of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126 and 132

NYHA classified participants in 4 classes: Class I: cardiac disease without limitations of physical activity. Ordinary physical activity caused no undue fatigue, palpitation, dyspnea or angina pain. Class II: cardiac disease with slight limitation of physical activity, comfortable at rest. Ordinary physical activity resulted in fatigue, palpitation, dyspnea or angina pain. Class III: cardiac disease with marked limitation of physical activity, comfortable at rest. Less than ordinary physical activity caused fatigue, palpitation, dyspnea or angina pain. Class IV: cardiac disease with inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or angina syndrome might be present even at rest. If any physical activity was undertaken, discomfort was increased. Participants with change from baseline were classified as improved (shifted from higher to lower class), unchanged (no change in class) or worsened (shifted from lower to higher class).

Time frame:
Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126, 132
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126 and 132
ParticipantsTafamidis 20 mg
Month 6: Worsened5
Month 6: Unchanged25
Month 6: Improved1
Month 18: Worsened7
Month 18: Unchanged17
Month 18: Improved3
Month 24: Worsened7
Month 24: Unchanged12
Month 24: Improved3
Month 30: Worsened4
Month 30: Unchanged14
Month 30: Improved2
Month 36: Worsened6
Month 36: Unchanged11
Month 36: Improved2
Month 42: Worsened10
Month 42: Unchanged5
Month 42: Improved2
Month 48: Worsened6
Month 48: Unchanged4
Month 48: Improved2
Month 54: Worsened6
Month 54: Unchanged6
Month 54: Improved0
Month 66: Worsened5
Month 66: Unchanged1
Month 66: Improved0
Month 72: Worsened2
Month 72: Unchanged5
Month 72: Improved0
Month 78: Worsened3
Month 78: Unchanged4
Month 78: Improved0
Month 84: Worsened3
Month 84: Unchanged3
Month 84: Improved0
Month 90: Worsened3
Month 90: Unchanged4
Month 90: Improved0
Month 96: Worsened3
Month 96: Unchanged1
Month 96: Improved1
Month 102: Worsened2
Month 102: Unchanged2
Month 102: Improved1
Month 108: Worsened2
Month 108: Unchanged1
Month 108: Improved2
Month 114: Worsened2
Month 114: Unchanged2
Month 114: Improved0
Month 120: Worsened3
Month 120: Unchanged1
Month 120: Improved0
Month 126: Worsened1
Month 126: Unchanged1
Month 126: Improved0
Month 132: Worsened1
Month 132: Unchanged0
Month 132: Improved0
SecondaryChange From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 132

6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, the total distance that a participant could walk in 6 minutes was evaluated.

Time frame:
Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 132
Reported as:
Mean · meters
Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 132
metersTafamidis 20 mg
Change at Month 62.9 ± 60.64
Change at Month 18-21.6 ± 108.19
Change at Month 24-15.7 ± 78.39
Change at Month 30-44.5 ± 111.67
Change at Month 36-63.5 ± 101.37
Change at Month 42-95.2 ± 124.79
Change at Month 48-110.9 ± 128.57
Change at Month 54-127.8 ± 124.01
Change at Month 66-63.2 ± 114.20
Change at Month 72-139.5 ± 210.18
Change at Month 78-94.3 ± 177.01
Change at Month 84-100.3 ± 151.71
Change at Month 90-97.6 ± 125.50
Change at Month 96-118.9 ± 114.20
Change at Month 102-82.3 ± 19.30
Change at Month 108-141.9 ± 112.29
Change at Month 114-166.9 ± 137.23
Change at Month 120-184.5 ± 82.22
Change at Month 132-289.6
SecondaryNumber of Participants Categorized Based on Total Distance Walked During 6 Minute Walk Test (6MWT) at Baseline, Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126 and 132

6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants were categorized based on the total distance walked as Level 1 = total distance walked \< 300 meter; Level 2 = total distance walked between 300 to 374.9 meter; Level 3 = total distance walked between 375 to 449.9 meter; Level 4 = total distance walked \>=450 meter.

Time frame:
Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126, 132
Reported as:
Count of participants · Participants
Number of Participants Categorized Based on Total Distance Walked During 6 Minute Walk Test (6MWT) at Baseline, Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126 and 132
ParticipantsTafamidis 20 mg
Baseline: Level 18
Baseline: Level 210
Baseline: Level 37
Baseline: Level 45
Month 6: Level 17
Month 6: Level 29
Month 6: Level 39
Month 6: Level 45
Month 18:Level 15
Month 18: Level 25
Month 18: Level 38
Month 18: Level 43
Month 24: Level 13
Month 24: Level 27
Month 24: Level 34
Month 24: Level 46
Month 30: Level 15
Month 30: Level 26
Month 30: Level 36
Month 30: Level 41
Month 36: Level 15
Month 36: Level 24
Month 36: Level 36
Month 36: Level 42
Month 42: Level 19
Month 42: Level 22
Month 42: Level 34
Month 42: Level 41
Month 48: Level 15
Month 48: Level 21
Month 48: Level 35
Month 48: Level 40
Month 54: Level 17
Month 54: Level 22
Month 54: Level 31
Month 54: Level 41
Month 66: Level 12
Month 66: Level 21
Month 66: Level 31
Month 66: Level 40
Month 72: Level 12
Month 72: Level 20
Month 72: Level 31
Month 72: Level 40
Month 78: Level 12
Month 78: Level 20
Month 78: Level 31
Month 78: Level 40
Month 84: Level 12
Month 84: Level 22
Month 84: Level 30
Month 84: Level 40
Month 90: Level 13
Month 90: Level 21
Month 90: Level 32
Month 90: Level 40
Month 96: Level 13
Month 96: Level 21
Month 96: Level 30
Month 96: Level 40
Month 102: Level 10
Month 102: Level 22
Month 102: Level 31
Month 102: Level 40
Month 108: Level 13
Month 108: Level 22
Month 108: Level 30
Month 108: Level 40
Month 114: Level 13
Month 114: Level 21
Month 114: Level 30
Month 114: Level 40
Month 120: Level 11
Month 120: Level 22
Month 120: Level 30
Month 120: Level 40
Month 132: Level 11
Month 132: Level 20
Month 132: Level 30
Month 132: Level 40
SecondaryChange From Baseline in Dyspnea and Fatigue Scores During 6 Minute Walk Test (6MWT) at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 132

6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. Dyspnea: participants were asked to rate the difficulty of their breathing, pre-walk and post-walk at each visit, on a scale of range 0 (no breathlessness at all) to 10 (maximum breathlessness). Higher scores indicated more severity. Fatigue: participants were asked to rate the how tired they felt, pre-walk and post-walk at each visit, on a scale of range 0 (not at all) to 10 (maximal) Higher scores indicated more fatigue. At each visit, scores for pre-walk test, post-walk test and within visit difference (difference from post-walk to pre-walk) were evaluated. Change from baseline was calculated for each pre-walk test, post-walk test and within visit difference at specified visits.

Time frame:
Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 132
Reported as:
Mean · units on a scale
Change From Baseline in Dyspnea and Fatigue Scores During 6 Minute Walk Test (6MWT) at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 132
units on a scaleTafamidis 20 mg
Dyspnea: Change at Month 6, Pre walk0.3 ± 1.32
Dyspnea: Change at Month 6, Post walk0.9 ± 1.54
Dyspnea: Change at Month 6,Within Visit Difference0.6 ± 1.56
Dyspnea: Change at Month 18, Pre walk0.3 ± 1.11
Dyspnea: Change at Month 18, Post walk0.8 ± 1.40
Dyspnea:Change at Month 18,Within Visit Difference0.6 ± 1.93
Dyspnea: Change at Month 24, Pre walk0.3 ± 0.75
Dyspnea: Change at Month 24, Post walk1.5 ± 1.91
Dyspnea:Change at Month 24,Within Visit Difference1.1 ± 2.02
Dyspnea: Change at Month 30, Pre walk0.2 ± 0.47
Dyspnea: Change at Month 30, Post walk1.2 ± 1.27
Dyspnea:Change at Month 30,Within Visit Difference1.0 ± 1.36
Dyspnea: Change at Month 36, Pre walk0.1 ± 1.36
Dyspnea: Change at Month 36, Post walk-0.2 ± 2.68
Dyspnea:Change at Month 36,Within Visit Difference-0.3 ± 1.97
Dyspnea: Change at Month 42, Pre walk0.5 ± 0.90
Dyspnea: Change at Month 42, Post walk1.0 ± 1.45
Dyspnea:Change at Month 42,Within Visit Difference0.5 ± 1.53
Dyspnea: Change at Month 48, Pre walk0.6 ± 1.17
Dyspnea: Change at Month 48, Post walk1.3 ± 0.98
Dyspnea:Change at Month 48,Within Visit Difference0.8 ± 1.64
Dyspnea: Change at Month 54, Pre walk0.4 ± 1.56
Dyspnea: Change at Month 54, Post walk1.0 ± 1.93
Dyspnea:Change at Month 54,Within Visit Difference0.6 ± 1.91
Dyspnea: Change at Month 66, Pre walk1.4 ± 1.11
Dyspnea: Change at Month 66, Post walk1.5 ± 1.29
Dyspnea:Change at Month 66,Within Visit Difference0.1 ± 1.18
Dyspnea: Change at Month 72, Pre walk0.8 ± 1.44
Dyspnea: Change at Month 72, Post walk0.7 ± 1.15
Dyspnea:Change at Month 72,Within Visit Difference-0.2 ± 0.29
Dyspnea: Change at Month 78, Pre walk2.2 ± 2.02
Dyspnea: Change at Month 78, Post walk0.7 ± 0.58
Dyspnea:Change at Month 78,Within Visit Difference-1.5 ± 1.50
Dyspnea: Change at Month 84, Pre walk-0.1 ± 0.85
Dyspnea: Change at Month 84, Post walk0.5 ± 1.00
Dyspnea:Change at Month 84,Within Visit Difference0.6 ± 1.70
Dyspnea: Change at Month 90, Pre walk0.6 ± 0.66
Dyspnea: Change at Month 90, Post walk-0.8 ± 2.32
Dyspnea:Change at Month 90,Within Visit Difference-1.4 ± 2.20
Dyspnea: Change at Month 96, Pre walk1.0 ± 1.41
Dyspnea: Change at Month 96, Post walk1.3 ± 1.50
Dyspnea:Change at Month 96,Within Visit Difference0.3 ± 2.36
Dyspnea: Change at Month 102, Pre walk-0.3 ± 0.58
Dyspnea: Change at Month 102, Post walk-1.3 ± 4.04
Dyspnea:Change at Month102,Within Visit Difference-1.0 ± 3.46
Dyspnea: Change at Month 108, Pre walk1.7 ± 2.82
Dyspnea: Change at Month 108, Post walk0.7 ± 4.97
Dyspnea:Change at Month108,Within Visit Difference-1.0 ± 2.81
Dyspnea: Change at Month 114, Pre walk0.4 ± 1.80
Dyspnea: Change at Month 114, Post walk0.1 ± 0.63
Dyspnea:Change at Month114,Within Visit Difference-0.3 ± 1.19
Dyspnea: Change at Month 120, Pre walk0.3 ± 1.53
Dyspnea: Change at Month 120, Post walk-0.8 ± 1.04
Dyspnea:Change at Month120,Within Visit Difference-1.2 ± 2.47
Dyspnea: Change at Month 132, Pre walk-1.0
Dyspnea: Change at Month 132, Post walk-1.0
Dyspnea:Change at Month132,Within Visit Difference0.0
Fatigue: Change at Month 6, Pre walk0.2 ± 1.69
Fatigue: Change at Month 6, Post walk0.7 ± 2.82
Fatigue:Change at Month 6,Within Visit Difference0.4 ± 2.92
Fatigue: Change at Month 18, Pre walk0.0 ± 2.13
Fatigue: Change at Month 18, Post walk0.2 ± 1.40
Fatigue:Change at Month 18,Within Visit Difference0.2 ± 2.51
Fatigue: Change at Month 24, Pre walk0.1 ± 1.66
Fatigue: Change at Month 24, Post walk1.0 ± 2.33
Fatigue:Change at Month 24,Within Visit Difference0.9 ± 2.97
Fatigue: Change at Month 30, Pre walk-0.4 ± 1.58
Fatigue: Change at Month 30, Post walk0.9 ± 1.65
Fatigue:Change at Month 30,Within Visit Difference1.3 ± 2.23
Fatigue: Change at Month 36, Pre walk-0.2 ± 2.29
Fatigue: Change at Month 36, Post walk0.8 ± 2.05
Fatigue:Change at Month 36,Within Visit Difference1.0 ± 2.76
Fatigue: Change at Month 42, Pre walk0.4 ± 1.76
Fatigue: Change at Month 42, Post walk1.6 ± 1.86
Fatigue:Change at Month 42,Within Visit Difference1.2 ± 2.86
Fatigue: Change at Month 48, Pre walk0.6 ± 1.26
Fatigue: Change at Month 48, Post walk1.5 ± 1.84
Fatigue:Change at Month 48,Within Visit Difference0.9 ± 2.38
Fatigue: Change at Month 54, Pre walk0.5 ± 1.57
Fatigue: Change at Month 54, Post walk0.5 ± 1.90
Fatigue:Change at Month 54,Within Visit Difference-0.1 ± 1.97
Fatigue: Change at Month 66, Pre walk0.3 ± 0.50
Fatigue: Change at Month 66, Post walk0.5 ± 2.38
Fatigue:Change at Month 66,Within Visit Difference0.3 ± 2.22
Fatigue: Change at Month 72, Pre walk2.0 ± 1.73
Fatigue: Change at Month 72, Post walk1.0 ± 1.73
Fatigue:Change at Month 72,Within Visit Difference-1.0 ± 0.00
Fatigue: Change at Month 78, Pre walk2.0 ± 2.00
Fatigue: Change at Month 78, Post walk1.0 ± 2.65
Fatigue:Change at Month 78,Within Visit Difference-1.0 ± 1.00
Fatigue: Change at Month 84, Pre walk0.0 ± 0.82
Fatigue: Change at Month 84, Post walk0.4 ± 1.11
Fatigue:Change at Month 84,Within Visit Difference0.4 ± 1.49
Fatigue: Change at Month 90, Pre walk1.3 ± 1.75
Fatigue: Change at Month 90, Post walk-0.3 ± 2.07
Fatigue:Change at Month 90,Within Visit Difference-1.7 ± 3.27
Fatigue: Change at Month 96, Pre walk0.8 ± 1.50
Fatigue: Change at Month 96, Post walk0.0 ± 0.82
Fatigue:Change at Month 96,Within Visit Difference-0.8 ± 1.71
Fatigue: Change at Month 102, Pre walk1.0 ± 2.65
Fatigue: Change at Month 102, Post walk-0.7 ± 1.53
Fatigue:Change at Month102,Within Visit Difference-1.7 ± 1.15
Fatigue: Change at Month 108, Pre walk1.8 ± 2.77
Fatigue: Change at Month 108, Post walk0.9 ± 3.54
Fatigue:Change at Month108,Within Visit Difference-0.9 ± 1.14
Fatigue: Change at Month 114, Pre walk1.0 ± 2.16
Fatigue: Change at Month 114, Post walk-0.1 ± 0.85
Fatigue:Change at Month114,Within Visit Difference-1.1 ± 1.44
Fatigue: Change at Month 120, Pre walk0.0 ± 1.00
Fatigue: Change at Month 120, Post walk-1.2 ± 0.76
Fatigue:Change at Month120,Within Visit Difference-1.2 ± 1.76
Fatigue: Change at Month 132, Pre walk-1.0
Fatigue: Change at Month 132, Post walk-0.5
Fatigue:Change at Month132,Within Visit Difference0.5
SecondaryNumber of Participants Categorized on Basis of Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 132

6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. Participants were asked to walk as far as possible for 6 minutes at a pace that was comfortable to them, and were permitted to slow down, to stop, and to rest as necessary. In this outcome measure, participants on basis of change from baseline in total distance walked were categorized as worsened, unchanged or improved. If distance walked at a visit was greater than distance walked at baseline, then categorized as 'improved'. If distance walked at a visit was equal to distance walked at baseline, then categorized as 'unchanged'. If distance walked at a visit was less than distance walked at baseline, then categorized as 'worsened'.

Time frame:
Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 132
Reported as:
Count of participants · Participants
Number of Participants Categorized on Basis of Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 132
ParticipantsTafamidis 20 mg
Month 6: Worsened5
Month 6: Unchanged20
Month 6: Improved5
Month 18: Worsened9
Month 18: Unchanged7
Month 18: Improved5
Month 24: Worsened6
Month 24: Unchanged10
Month 24: Improved4
Month 30: Worsened9
Month 30: Unchanged4
Month 30: Improved5
Month 36: Worsened8
Month 36: Unchanged7
Month 36: Improved2
Month 42: Worsened9
Month 42: Unchanged6
Month 42: Improved1
Month 48: Worsened7
Month 48: Unchanged3
Month 48: Improved1
Month 54: Worsened7
Month 54: Unchanged4
Month 54: Improved0
Month 66: Worsened3
Month 66: Unchanged1
Month 66: Improved0
Month 72: Worsened2
Month 72: Unchanged1
Month 72: Improved0
Month 78: Worsened2
Month 78: Unchanged1
Month 78: Improved0
Month 84: Worsened3
Month 84: Unchanged1
Month 84: Improved0
Month 90: Worsened4
Month 90: Unchanged1
Month 90: Improved1
Month 96: Worsened3
Month 96: Unchanged1
Month 96: Improved0
Month 102: Worsened2
Month 102: Unchanged1
Month 102: Improved0
Month 108: Worsened4
Month 108: Unchanged1
Month 108: Improved0
Month 114: Worsened3
Month 114: Unchanged1
Month 114: Improved0
Month 120: Worsened3
Month 120: Unchanged0
Month 120: Improved0
Month 132: Worsened1
Month 132: Unchanged0
Month 132: Improved0
SecondaryChange From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Summary Score at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126 and 132

KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: physical limitation, social limitation, quality of life, self-efficacy, symptom stability, symptom frequency, symptom burden, and total symptoms (calculated as the mean of symptom frequency and symptom burden scores). Two summary scores were calculated: clinical summary (calculated as mean of physical limitation and total symptom scores) and overall summary (calculated as mean of physical limitation, social limitation, total symptoms, and quality of life scores). Each domain and both summary scores were scaled to range from 0 (worse health status) to 100 (best health status); higher scores represented better health status.

Time frame:
Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126, 132
Reported as:
Mean · units on a scale
Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Summary Score at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126 and 132
units on a scaleTafamidis 20 mg
Overall Summary Score: Change at Month 6-2.12 ± 12.423
Overall Summary Score: Change at Month 18-4.58 ± 18.926
Overall Summary Score: Change at Month 24-2.94 ± 16.247
Overall Summary Score: Change at Month 30-5.41 ± 17.695
Overall Summary Score: Change at Month 36-6.86 ± 18.525
Overall Summary Score: Change at Month 42-12.76 ± 23.646
Overall Summary Score: Change at Month 48-13.22 ± 24.893
Overall Summary Score: Change at Month 54-14.99 ± 23.688
Overall Summary Score: Change at Month 66-1.77 ± 30.476
Overall Summary Score: Change at Month 720.41 ± 23.317
Overall Summary Score: Change at Month 78-3.60 ± 24.231
Overall Summary Score: Change at Month 84-3.72 ± 32.770
Overall Summary Score: Change at Month 90-0.28 ± 30.296
Overall Summary Score: Change at Month 96-17.84 ± 47.842
Overall Summary Score: Change at Month 102-12.63 ± 40.904
Overall Summary Score: Change at Month 108-1.19 ± 35.375
Overall Summary Score: Change at Month 114-2.99 ± 37.897
Overall Summary Score: Change at Month 120-35.55 ± 9.023
Overall Summary Score: Change at Month 126-39.32 ± 8.102
Overall Summary Score: Change at Month 132-40.10
Clinical Summary Score: Change at Month 6-3.00 ± 11.650
Clinical Summary Score: Change at Month 18-6.66 ± 17.340
Clinical Summary Score: Change at Month 24-2.87 ± 15.875
Clinical Summary Score: Change at Month 30-7.80 ± 17.497
Clinical Summary Score: Change at Month 36-9.53 ± 17.700
Clinical Summary Score: Change at Month 42-17.05 ± 22.804
Clinical Summary Score: Change at Month 48-15.67 ± 24.854
Clinical Summary Score: Change at Month 54-16.90 ± 21.295
Clinical Summary Score: Change at Month 66-3.45 ± 27.219
Clinical Summary Score: Change at Month 72-1.82 ± 21.558
Clinical Summary Score: Change at Month 78-7.13 ± 22.422
Clinical Summary Score: Change at Month 84-6.53 ± 29.881
Clinical Summary Score: Change at Month 90-2.47 ± 24.198
Clinical Summary Score: Change at Month 96-19.27 ± 42.768
Clinical Summary Score: Change at Month 102-15.10 ± 31.690
Clinical Summary Score: Change at Month 108-3.26 ± 27.764
Clinical Summary Score: Change at Month 114-4.69 ± 32.213
Clinical Summary Score: Change at Month 120-42.45 ± 11.417
Clinical Summary Score: Change at Month 126-38.02 ± 14.731
Clinical Summary Score: Change at Month 132-40.63
SecondaryNumber of Participants With Abnormalities in Echocardiography

Echocardiography abnormalities included: absent respiratory variation of inferior vena cava, any valve thickening, aortic valve thickening, decreased respiratory variation of inferior vena cava, dilated inferior vena cava, E deceleration time less than or equal to (\<=) 150 millisecond, E wave/A Wave (E/A) ratio \>=2, ejection fraction \< 50%, isovolumic relaxation time (IVRT) \<=70 millisecond, left ventricular posterior wall thickness \>=13 millimeter (mm), left ventricular septal thickness \>= 13 mm, mitral valve thickening, pericardial effusion, pulmonary valve thickening, right ventricular thickness \>=7 mm, tricuspid valve thickening, ratio between early mitral inflow velocity and mitral annular early diastolic velocity (e/e') Lateral greater than (\>) 15, e/e' Septal \>15.

Time frame:
Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Echocardiography
ParticipantsTafamidis 20 mg
Number of Participants With Abnormalities in Echocardiography31
SecondaryChange From Baseline in Troponin I and Troponin T Serum Levels at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 126

Troponin I and troponin T are the cardiac markers. Troponin I and troponin T are part of the troponin complex, where troponin I is bound to actin in thin myofilaments and troponin T is bound to tropomyosin. Higher level of these markers is indicative of heart damage.

Time frame:
Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 126
Reported as:
Mean · nanogram per milliliter
Change From Baseline in Troponin I and Troponin T Serum Levels at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 126
nanogram per milliliterTafamidis 20 mg
Troponin I: Change at Month 6-0.016 ± 0.0533
Troponin I: Change at Month 180.032 ± 0.1307
Troponin I: Change at Month 240.023 ± 0.0986
Troponin I: Change at Month 300.022 ± 0.1038
Troponin I: Change at Month 360.029 ± 0.1099
Troponin I: Change at Month 420.042 ± 0.1409
Troponin I: Change at Month 480.058 ± 0.1409
Troponin I: Change at Month 540.042 ± 0.1226
Troponin I: Change at Month 66-0.012 ± 0.0133
Troponin I: Change at Month 72-0.010 ± 0.0183
Troponin I: Change at Month 78-0.013 ± 0.0208
Troponin I: Change at Month 84-0.008 ± 0.0096
Troponin I: Change at Month 90-0.003 ± 0.0293
Troponin I: Change at Month 96-0.008 ± 0.0150
Troponin I: Change at Month 102-0.010 ± 0.0356
Troponin I: Change at Month 1080.000 ± 0.0071
Troponin I: Change at Month 1140.000 ± 0.0271
Troponin I: Change at Month 1200.000 ± 0.0141
Troponin I: Change at Month 1260.005 ± 0.0354
Troponin T: Change at Month 6-0.0007 ± 0.01710
Troponin T: Change at Month 180.0271 ± 0.07429
Troponin T: Change at Month 240.0132 ± 0.03286
Troponin T: Change at Month 300.0166 ± 0.02227
Troponin T: Change at Month 360.0205 ± 0.03049
Troponin T: Change at Month 420.0329 ± 0.05665
Troponin T: Change at Month 480.0510 ± 0.09562
Troponin T: Change at Month 540.0562 ± 0.13264
Troponin T: Change at Month 660.0050 ± 0.02588
Troponin T: Change at Month 72-0.0055 ± 0.01714
Troponin T: Change at Month 780.0000 ± 0.01732
Troponin T: Change at Month 84-0.0003 ± 0.01415
Troponin T: Change at Month 900.0026 ± 0.00962
Troponin T: Change at Month 96-0.0037 ± 0.00551
Troponin T: Change at Month 1020.0098 ± 0.01461
Troponin T: Change at Month 1080.0100 ± 0.00707
Troponin T: Change at Month1140.0100 ± 0.00816
Troponin T: Change at Month 1200.0150 ± 0.02121
Troponin T: Change at Month 1260.0000
SecondaryChange From Baseline in Amino-Terminal B-type Natriuretic Peptide (NT-proBNP) Serum Level at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 126

NT-proBNP was biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ LV wall stress).

Time frame:
Baseline, Month 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126
Reported as:
Mean · nanogram per milliliter
Change From Baseline in Amino-Terminal B-type Natriuretic Peptide (NT-proBNP) Serum Level at Months 6, 18, 24, 30, 36, 42, 48, 54, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120 and 126
nanogram per milliliterTafamidis 20 mg
Change at Month 666.0 ± 2164.66
Change at Month 18492.0 ± 2455.65
Change at Month 24211.5 ± 2119.01
Change at Month 30701.8 ± 2423.16
Change at Month 361063.5 ± 2813.85
Change at Month 422510.2 ± 5143.47
Change at Month 483761.2 ± 7892.80
Change at Month 541668.1 ± 2677.27
Change at Month 66433.3 ± 493.76
Change at Month 72625.5 ± 471.41
Change at Month 78707.7 ± 236.53
Change at Month 84348.5 ± 700.98
Change at Month 90283.7 ± 971.53
Change at Month 961453.0 ± 2193.75
Change at Month 1021439.0 ± 2032.43
Change at Month 108346.4 ± 1279.58
Change at Month 114465.7 ± 790.48
Change at Month 1201232.0 ± 667.51
Change at Month 1261249.0
SecondaryNumber of Participants With All-cause Hospitalization and Cardiac-related Hospitalization Events

All cause hospitalization was defined as any serious adverse event, which resulted in hospitalization. Cardiac-related hospitalization was any hospitalization meeting the following criteria: cardiac disorders or AE preferred term as chest discomfort, chest pain, death, cerebrovascular accident, embolic stroke, disease progression.

Time frame:
Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303
Reported as:
Count of participants · Participants
Number of Participants With All-cause Hospitalization and Cardiac-related Hospitalization Events
ParticipantsTafamidis 20 mg
All-cause Hospitalization27
Cardiac Related Hospitalization18
SecondaryTime to All-cause Mortality and Cardiac-Related Mortality

Time to death for all participants with a death date in Clinical Database, or censored at the last dose date + 28 days for those participants who were alive at the end of the study is reported.

Time frame:
Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303
Reported as:
Median · years
Time to All-cause Mortality and Cardiac-Related Mortality
yearsTafamidis 20 mg
All-Cause Mortality4.1 (1.9 to 5.4)
Cardiac-related mortality5.9 (3.0 to NA)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and all non-serious adverse events.

Time frame:
Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsTafamidis 20 mg
Participants with AEs31
Participants with SAEs29
SecondaryNumber of Participants With Treatment-Related Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and all non-serious adverse events. Relatedness to study drug was assessed by the investigator as (Yes/No).

Time frame:
Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsTafamidis 20 mg
Participant with AEs7
Participant with SAEs4
SecondaryNumber of Participants With Clinically Significant Physical Examination Findings

Physical examination included examination of general appearance, endocrine, head and neck, cardiovascular, eyes, abdomen, ears, skin, nose, musculoskeletal, throat, neurological, respiratory, immunologic/allergies, genitourinary, hematologic/lymphatic. Clinical significance of any physical examination finding was judged by investigator.

Time frame:
Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Physical Examination Findings
ParticipantsTafamidis 20 mg
Number of Participants With Clinically Significant Physical Examination Findings19
SecondaryNumber of Participants With Any Concomitant Medications

Number of participants who used medication other than study drug were reported.

Time frame:
Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303
Reported as:
Count of participants · Participants
Number of Participants With Any Concomitant Medications
ParticipantsTafamidis 20 mg
Number of Participants With Any Concomitant Medications31
SecondaryNumber of Participants With Clinically Significant Electrocardiogram (ECG) Findings

ECG parameters included PR interval (millisecond), RR interval (millisecond), QRS interval (millisecond), QT and QTc interval (millisecond) and heart rate (beats per minute). Clinical significance of any ECG finding was judged by investigator.

Time frame:
Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings
ParticipantsTafamidis 20 mg
Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings1
SecondaryNumber of Participants With Laboratory Abnormalities

Laboratory parameters included hematology and biochemistry: alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen, gamma glutamyl transferase (GGT), creatinine, total bilirubin, international normalized ratio (INR), troponin I, troponin T, prothrombin time, sodium, globulin potassium, chloride, bicarbonate, cholesterol, calcium, uric acid, inorganic phosphorous, thyroid-stimulating hormone, glucose, total thyroxine (T4), free T4, total proteins, prealbumin (transthyretin), albumin, hemoglobin, platelets, hematocrit, white blood cell count, red blood cell count, neutrophils, packed cell volume, lymphocytes, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, eosinophils, mean corpuscular hemoglobin concentration, basophils, retinol-binding protein, Urinalysis: bilirubin, pH, blood (free Hb), protein, nitrite, glucose, urobilinogen, ketones, specific gravity.

Time frame:
Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsTafamidis 20 mg
Number of Participants With Laboratory Abnormalities27

Adverse events

Collected over Post-Month 12 up to Month 132 (approximately 10 years) of Study FX1B-303. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tafamidis 20 mg23/31 (74.2%)29/31 (93.5%)30/31 (96.8%)
Most frequent serious events
Showing 10 of 81
Most frequent serious events
EventTafamidis 20 mg
CARDIAC FAILURE CONGESTIVECardiac disorders9/31
CARDIAC FAILURECardiac disorders6/31
FALLInjury, poisoning and procedural complications6/31
FAMILIAL AMYLOIDOSISCongenital, familial and genetic disorders4/31
CHEST PAINGeneral disorders3/31
CELLULITISInfections and infestations3/31
DEHYDRATIONMetabolism and nutrition disorders3/31
ATRIAL TACHYCARDIACardiac disorders2/31
FAECALOMAGastrointestinal disorders2/31
ASTHENIAGeneral disorders2/31
Most frequent other events
Showing 10 of 84
Most frequent other events
EventTafamidis 20 mg
FALLInjury, poisoning and procedural complications13/31
CONSTIPATIONGastrointestinal disorders11/31
BACK PAINMusculoskeletal and connective tissue disorders11/31
FATIGUEGeneral disorders10/31
ARTHRALGIAMusculoskeletal and connective tissue disorders9/31
DYSPNOEARespiratory, thoracic and mediastinal disorders9/31
DEHYDRATIONMetabolism and nutrition disorders7/31
PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders7/31
SKIN LACERATIONInjury, poisoning and procedural complications7/31
URINARY TRACT INFECTIONInfections and infestations6/31

Baseline characteristics

The intent to treat (ITT) population included all participants who were enrolled and received at least 1 dose of study medication, had baseline and at least 1 post-baseline cardiac measure.

Age, Continuous
Age, Continuous(years)Tafamidis 20 mg
Mean77.6 ± 4.89
Sex: Female, Male
Sex: Female, Male(Participants)Tafamidis 20 mg
Female3
Male28
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tafamidis 20 mg
Caucasian27
Afro-caribbean1
African American3
08

Study locations

7 sites
  • Emory University School of Medicine
    Atlanta, Georgia 30322-4510, United States
  • The University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE)
    New York, New York 10034-1159, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2009 to primary completion in Nov 2019, 121 months.

Results were first posted in Jan 2021, 1 year 1 month after primary completion.

Of 20 phase 3 interventional studies under Cardiomyopathies, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 103. This study's 121 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2009
First posted
Jul 8, 2009
StartActual
Sep 30, 2009
Primary completionActual
Nov 20, 2019
CompletionActual
Nov 20, 2019
Results first posted
Jan 5, 2021
Last update
Jan 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00935012
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 8, 2009
Start date
Sep 30, 2009
Primary completion
Nov 20, 2019
Completion
Nov 20, 2019
Results posted
Jan 5, 2021
Last update
Jan 5, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafamidis

Start the discussion